Discussion
This study shows that there has been a large increase in the number of words (337%) and items of information (273%) in reports of mastectomy and colectomy specimens. It During the study period the workload of the laboratory (as measured by number of request forms) has increased by over 10 times. Although the number of staff has also increased, there has not been a reduction in the workload of an individual so the increase in report length cannot be related to this. The increase in number of words is not related to the mode of reporting because the reports have always been handwritten by the pathologists before typing. The ratio of words per item of information varies over the study period, but the figure in 1990 is only 1-3 words more than in 1940, so there has only been a slight increase in verbosity. There has been an increase in the number of trainee pathologists in the department and they may have been writing longer reports in preparation for examinations; it would be interesting to see ifthe same increases have occurred in district general hospitals.
With the wide availability of word-processing equipment a long report may not take as much secretarial time to produce as a shorter report created on a typewriter. An increase in efficiency using this technology is facilitated by the development of standardised reports for certain types of specimens. In the departments included in this study word-processors were not used to prepare surgical pathology reports so any increase in report length would increase the amount of secretarial work. The Welcan system has been described only in the past decade and it was not possible to apply it retrospectively to the specimens in this study to ascertain whether the increase in words and information was reflected in an increase in Welcan units. The results of this study indicate the need to review the length and informational content of histopathological reports when assessing total laboratory workload. Children with cystic fibrosis tend to have malabsorption and are therefore at risk of vitamin K deficiency.' The findings of a recent study, however, showed that median values of plasma vitamin K concentrations in such patients were in the same ranges as those of healthy controls.2 To assess vitamin K concentration among our patients with cystic fibrosis, we assayed plasma PIVKA-II (prothrombin induced by absence of vitamin K), which is an indicator of early vitamin K deficiency.3 Indeed, certain coagulation factors (II, VII, IX and X) must be processed in liver endoplasmic reticulum by vitamin K dependent enzymes, a process that is absent in vitamin K deficiency or in patients receiving oral anticoagulants: the plasma concentrations of PIVKA-II are then increased.
Methods
Forty three patients with cystic fibrosis were studied (mean age 10; range three months to 23 years). Four had liver damage. All but two received daily oral vitamin K (5-10 mg/day). All received oral prophylaxis with vitamin E (atocopherol) (100-1000 mg/day). Using a previously described method,3 involving staphylocoagulase and adsorbed undiluted citrated plasma, we assayed the plasma PIVKA-II concentrations in our patients. The thrombin-coagulase formed was measured on a chromogenic substrate, and the results were expressed in mU/ml. The with increased PIVKA-II concentrations had been taking antibiotics (ceftazidime, cefsulodine, thienamycin, ticarcilline), at the time the sample was collected. The difference between these two groups was significant: X2 test, p < 0-05. The difference between the mean (SD) PIVKA-II concentrations of patients who were not taking antibiotics (7 8 (12 4) mU/ml) and those who were (18 9 (14 8) mU/ml) was significant (p < 0 001; Mann-Whitney U test). Discussion Serum vitamin K concentration was not decreased in all our patients, only one, who had not received prophylactic treatment. We can therefore conclude that the vitamin K prophylaxis used was sufficient. But, although their vitamin K concentration was normal, some patients also had an increased PIVKA-II concentration: this was therefore not associated with vitamin K deficiency.
Increased PIVKA-II concentrations may be observed in contexts other than vitamin K deficiency: during oral anticoagulant treatment, hepatocellular carcinomas3 and the use of certain cephalosporins (moxalactam, cefamandole, cefoperazone).5 None of our patients had taken such drugs. We observed, however, a significant correlation between PIVKA-II concentrations and the administration of antibiotics. These have not previously been described as inhibiting gamma-carboxylation of PIVKA-II. Certain antibiotics seem to inhibit the carboxylation of the prothrombin and increase the plasma PIVKA-II concentration. The biochemical mechanism of this phenomenon none the less remains unknown. An increase in PIVKA-II was in any case associated with vitamin K deficiency.
Vitamin E might also inhibit gamma-carboxylation of the vitamin K dependent enzymes, and this might explain the increased PIVKA-II concentrations in patients with cystic fibrosis.6 But we found no correlation between PIVKA-II and vitamin E concentrations.
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